乳酸性儿科ABPM缺乏真菌敏感性,对抗IL-5有反应
Mari Mizutani1, Takayasu Nomura1, Akiko Nakaoka1
1Department of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
The journal of allergy and clinical immunology. Global
|December 29, 2025
概括
一名患有过敏性支气管肺神经菌根症的儿科患者通过使用抗干白素-5 (IL-5) 疗法实现了缓解. 这一案例突出显示了高衰减粘液作为诊断标记物和呼吸道疾病中的异氨酸性炎症.
科学领域:
- 儿科肺病学 儿科肺病学
- 过敏和免疫学 过敏和免疫学
- 医学真菌学 医学真菌学
背景情况:
- 过敏性支气管肺结核 (ABPM) 是一种过敏性肺部疾病.
- 在CT扫描中,高衰减粘液 (HAM) 可能表明ABPM.
- 氨酸性炎症在呼吸道疾病中起作用,即使没有IgE敏感性.
研究的目的:
- 报告一个儿科ABPM与HAM的病例.
- 评估在非IgE敏感的患者中抗干白素-5 (IL-5) 治疗的疗效.
- 为了强调HAM和eosinophilic炎症的诊断意义.
主要方法:
- 一个儿科病人的病例报告.
- 诊断成像:CT扫描中的高衰减粘液检测.
- 治疗干预:抗IL-5疗法.
- 对临床缓解和炎症标志物的评估.
主要成果:
- 患者出现了ABPM和HAM,但没有真菌敏感性.
- 抗IL-5疗法导致症状和疾病完全缓解.
- 在这种情况下,HAM是关键的诊断指标.
- 尽管没有IgE介导的反应,但埃索诺菲尔炎症仍然存在.
结论:
- 高衰减粘液是儿童患者ABPM的宝贵诊断线索.
- 抗IL-5疗法可以有效地治疗带有异敏性炎症的ABPM,即使在非IgE主导的表现中也是如此.
- 这一案例强调了在像ABPM这样的疾病中考虑异性气道炎症的重要性.
相关概念视频
Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
Asthma-I: Introduction
3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K


